Formulation: A solid
Formal Name: L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valine, trifluoroacetate salt
Purity: ≥98%
Formula Markup: C48H78N12O16 • XCF3COOH
Formula Weight: 1079,2
Shelf life (days): 1460
Notes: EGFRvIII peptide is a synthetic peptide that corresponds to the fusion junction of EGFRvIII, a tumor-specific, constitutively active variant of EGFR that lacks amino acids 6-273 of wild-type EGFR.{66481,66482} It binds to MHC class I subtype HLA-A*0201-positive T2 cells when used at a concentration of 25 µg/ml.{66481} EGFRvIII peptide induces antigen presentation in dendritic cells derived from isolated human peripheral blood mononuclear cells (PBMCs), which stimulates activation of, and IFN-γ production by, CD8+ cytotoxic T lymphocytes. Immunization with EGFRvIII peptide (15 µg/animal), in combination with the toll-like receptor 5 (TLR5) agonist flagellin B, increases the number of CD8+ T cells and decreases the number of regulatory T cells (Tregs) in the brain, reduces tumor volume, and increases survival rate in an orthotopic GL261 glioblastoma mouse xenograft model.{66482}
English
Deutsch
